Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease
Trial Parameters
Brief Summary
This trials aims to assess, in 240 eligible patients with coronary heart disease, the effects on level of high-sensitivity C-reactive protein (hsCRP) changes from baseline to 12 weeks of Xuesaitong Soft Capsules.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years old 2. Chronic coronary artery disease: meet any of the following conditions, and the condition is stable for at least 3 months: 1. History of myocardial infarction 2. Have received coronary interventional therapy 3. There are symptoms of myocardial ischemia (such as chest pain) and objective evidence (stress electrocardiogram or stress myocardial perfusion imaging indicated myocardial ischemia or coronary artery stenosis ≥50% ) 3. High-sensitivity C-reactive protein ≥2mg/L 4. Currently taking moderate or above intensity statins lipid-lowering drugs 5. Currently taking antiplatelet drugs 6. Sign informed consent Exclusion Criteria: * Patients fulfilling any of the following criteria are not eligible for inclusion in this trial: 1. Acute coronary syndrome occurred or received percutaneous coronary intervention therapy within the past 3 months 2. Previously received coronary artery bypass grafting 3. Stroke occurred within the previous 3 months 4. Sym